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Background: In view of the prevalence of oxidative stress in chronic kidney disease (CKD) patients, the loss of low-
molecular-weight biomolecules by hemodialysis and the antioxidant potential of some uremic solutes that accumulate in
CKD, we used in vitro model systems to test the antioxidant potential of the following uremic solutes: uric acid, hippuric
acid, p-cresol, phenol, methylguanidine, L-arginine, L-tyrosine, creatinine and urea.
Methods: The in vitro antioxidant efficiencies of the uremic solutes, isolated or in mixtures, were tested with the
following assays: i) ABTS radical cation decolorization assay; ii) hypochlorous acid (HOCl/OCl−) scavenging activity; iii)
superoxide anion radical (O2
•-) scavenging activity; iv) crocin bleaching assay (capture of peroxyl radical, ROO•); v) hydrogen
peroxide (H2O2) scavenging activity.
Results: Four of the tested uremic solutes (p-cresol, phenol, L-tyrosine, uric acid) were effective antioxidants and their IC50
were found in three model systems: ABTS•+, HOCl/OCl− and crocin bleaching assay. In the 4-solutes mixtures, each one of
the solute captured 12.5% for the IC50 of the mixture to ABTS
•+ or HOCl/OCl−, exhibiting a virtually exact additive effect. In
the 2-solutes mixtures, for ROO• capture, it was observed the need of more mass of uremic solutes to reach an IC50 value
that was higher than the projected IC50, obtained from the IC50 of single solutes (25% of each, in the binary mixtures) in
the same assay. In model systems for O2
•- and H2O2, none of the uremic solutes showed scavenging activity.
Conclusions: The use of the IC50 as an analytical tool to prepare and analyze mixtures allows the determination of their
scavenging capacities and may be useful for the assessment of the antioxidant status of biological samples under
conditions of altered levels of the endogenous antioxidant network and/or in the employment and monitoring of
exogenous antioxidant therapy.
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Oxidative stress has been postulated as a cause and also
an exacerbating factor of various diseases, including the
chronic kidney diseases (CKD) [1]. Increased reactive
oxygen species (ROS) production is often caused by the
dysfunctional mitochondria formed in the most import-
ant conditions that lead to CKD [2]; impairment in the
antioxidant defenses and endogenous activation of* Correspondence: brunetti@fcfar.unesp.br
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unless otherwise stated.phagocytes have been also cited as potential factors re-
sponsible for oxidative stress in CKD [3]. Over the last
years it has become clear that the association among in-
creased ROS generation, impaired endogenous antioxi-
dant systems and low nitric oxide (NO) bioavailability
plays a crucial role in the development of the endothelial
dysfunction in CKD patients [4,5], predisposing them to
long-term complications closely related to atheroscler-
osis and cardiovascular morbidity [6,7].
During the progression of the renal disease, loss of
kidney function is accompanied by failing organ function
leading to accumulation of a series of compounds [8].
So, in the later stages of CKD, the treatment aims tohis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pairments caused by the reduced kidney function, via a
renal replacement therapy, in which hemodialysis (HD)
is the most common [2,9]. The primary goal of HD is to
restore the intracellular and extracellular fluid environ-
ment typical of normal kidney function [10]. However,
HD is considered an exacerbating factor for oxidative
stress in CKD patients, mainly attributed to the activa-
tion of neutrophils during forced passage of blood
through the dialysis circuits, provoking endogenous in-
flammatory processes with release of ROS [11]. Also,
loss of circulating low-molecular-weight dialyzable anti-
oxidants is also a consequence of HD. Taken together, it
is postulated that oxidative stress increases in CKD pa-
tients after HD session [12,13]. Ujhelyi and collaborators
[14] found that the decreased antioxidant capacity of
plasma ultrafiltrate from CKD patients on HD may be
due to the dialytic removal of some uremic solutes, in-
creasing the risk of low density lipoprotein (LDL) oxida-
tion and subsequent endothelial cell damage.
More than 90 uremic solutes removed from blood by
HD are reported, grouped according to their physico-
chemical properties [15]. In spite of the toxicity due to
the increased levels of uremic solutes in CKD patients, it
is crescent the data regarding the increased oxidative
stress after HD attributable to the loss of uremic solutes
[16-18], mainly uric acid. Blood levels of O2
•- are raised
in CKD patients and further increased after one session
of HD [13]. The controversial roles of uremic solutes in
CKD patients highlight to the importance of monitoring
their antioxidant status, which can be useful to bring in-
formation about the oxidative stress before and after
HD, weighting the need of employing antioxidant ther-
apy, as well to investigate the effectiveness of antioxidant
interventions.
The assessment in serum of the scavenging capacity
against ROS has been cited as a good indicator of the indi-
vidual defenses to oppose the oxidative stress [19]. The
ROS scavenging capacity in biological samples depends on
the nature of the reactive species, the molecular structure
of the antioxidants and the locus of this interaction. How-
ever, considering the myriad of molecules acting as anti-
oxidant in serum samples and the interactions among
them, it is often difficult to assess the relative contribution
of their individual antioxidants capacities [20].
Nowadays, efforts have been made to standardize an
in vitro analytical assay attempting to bring information
that can expand the actual knowledge of the antioxidant
effectiveness in biological samples. In this way, it seems
useful to develop analytical tools that allow the deter-
mination of the antioxidant capacity of mixtures com-
posed of endogenous and/or exogenous compounds,
such as in vitro model systems. Therefore, considering
that: i) the uremic solutes show different antioxidantcapacities and ii) the knowledge of their serum levels,
we believe that the use of an analytical method that al-
lows their individual scavenging capacity to be deter-
mined may be useful for the assessment of the oxidative
status in CKD and/or HD patients, as well as for the ef-
fectiveness of antioxidant interventions. Data obtained
may be useful to correlate with both the prevalence and
pathogenesis of cardiovascular diseases and the continu-
ity loss of renal function.
In this light, we investigated the antioxidant activity of
the commonest uremic solutes, isolated or in selected
mixtures, focusing on the involvement of certain ROS in
CKD. To this end, in vitro model systems were used to
assess the scavenging activity, with respect to the ABTS
cation radical (ABTS•+), superoxide anion radical (O2
•-),
hypochlorous acid (HOCl), hydrogen peroxide (H2O2)
and peroxyl radical (ROO•, crocin bleaching assay),
exhibited by the following uremic solutes: uric acid,
hippuric acid, p-cresol, phenol, methylguanidine, L-
arginine, L-tyrosine, creatinine and urea.
Methods
The uremic solutes creatinine, hippuric acid, uric acid,
methylguanidine, L-arginine and L-tyrosine were pur-
chased from Sigma-Aldrich, phenol and urea from
Merck, and p-cresol from Riedel de Haën.
Besides the uremic solutes, 6-hydroxy-2,5,7,8-tetra-
methylchroman-2-carboxylic acid (Trolox, Sigma Al-
drich, USA), a soluble synthetic analogue of vitamin E
with well-established antioxidant activity [21], was used
as a standard. Absorbance readings were taken in a mi-
croplate spectrophotometer (Biotek- Power Wave XS2),
or an OceanOptics USB 4000 for the tests with crocin,
with magnetic stirring and Peltier heating. The scaven-
ging capacities against oxidizing species were calculated
as the mean of triplicate tests, except for peroxyl radical
(ROO•) scavenging assay, which was performed in dupli-
cate assays. The concentrations reported are final con-
centrations in the assays.
ABTS radical cation decolorization assay
Antioxidant activity was assessed by the ABTS method,
as described by Re et al. [22], with modifications. The
ABTS•+ radical cation was generated by oxidation of
2,2′-azino-bis (3-ethylbenzthiazoline-6-sulphonic acid),
(ABTS, Sigma Aldrich, USA) (7 mmol/L) with potassium
persulfate (Sigma Aldrich, USA) (140 mmol/L) in the
dark at room temperature for 12 to 16 hours. This
ABTS•+ stock solution was diluted in sodium phosphate
buffer (10 mmol/L, pH 7.0) to an absorbance of 0.750 ±
0.020, at 734 nm. Various concentrations of uremic sol-
utes were then added, the reaction mixture was incu-
bated for 15 minutes in the dark at room temperature
and absorbance was read at 734 nm. The results were
Scheme 1 Reactions involved in the crocin bleaching with
termolysis of AAPH (adapted from Ordoudi and Tsimidou [58]. A,
represents an antioxidant (sample).
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of the 50% inhibitory concentration (IC50).
Superoxide anion radical (O2
•-) scavenging assay
The O2
•- was produced by reaction between reduced
nicotinamide adenine dinucleotide (NADH, Sigma Aldrich,
USA), phenazine methosulfate (PMS, Sigma Aldrich,
USA) and molecular oxygen [23]. The O2
•- generated
reacts with nitroblue tetrazolium (NBT, Sigma Aldrich,
USA), reducing it to a blue formazan, whose color in-
tensity is directly proportional to the radical concentra-
tion. The test was performed in sodium pyrophosphate
buffer (25 mmol/L, pH 8.3), containing PMS (372 μmol/L),
NBT (600 μmol/L), NADH (1560 μmol/L) and various
concentrations of uremic solutes. After 7 minutes at
room temperature, the absorbance was read at 560 nm
to determine the concentration of formazan [24]. The
assay in the absence of uremic solutes was used as a
control (100% reaction) and the reaction medium with-
out NADH was used as a reading blank. The results
were expressed as mean IC50 ± SEM.
Hypochlorous acid (HOCl/OCl−) scavenging assay
The antioxidant activity depends on the capacity of the
sample to capture HOCl/OCl−, preventing it from oxidiz-
ing 3,3′,5,5′- tetramethylbenzidine (TMB, Sigma Aldrich,
USA). TMB oxidation by HOCl/OCl− generates a blue
compound with maximum absorbance at 655 nm [25,26].
To produce a standard solution of OCl−, NaOCl was
diluted in 10 mmol/L NaOH and its concentration was
determined by its molar extinction coefficient (ε = 350
M-1 cm-1 at 292 nm) [27].
Various concentrations of uremic solutes in sodium phos-
phate buffer (50 mmol/L, pH 7.4) were incubated with
HOCl/OCl− (30 μmol/L) for 10 minutes. TMB (2.8 mmol/
L dissolved in 50% dimethylformamide with 0.01 mol/L po-
tassium iodide in 0.8 mol/L acetic acid) was then added
and incubated for 5 minutes at room temperature in the
dark and the absorbance were monitored at 655 nm, as de-
scribed by Dypbukt [26], with modifications. The assay
without uremic solutes was used as control (100% reaction)
and the absorbance of the reaction medium without HOCl
was used as a reading blank. The results were expressed as
mean IC50 ± SEM.
Peroxyl radical (ROO•) scavenging assay
The peroxyl radical (ROO•) is formed during the
process of lipoperoxidation (LPO) in aerated medium;
several model systems simulate this reaction to assess
the capacity of antioxidants to scavenge this type of
oxidative activity, including the protection against
bleaching of crocin.
The crocin bleaching assay was performed as de-
scribed by Tubaro et al. [28], by monitoring the decreasein crocin absorbance at 443 nm for 10 minutes, in a
competitive kinetics procedure. The reaction is initiated
by addition of the azo-compound 2,2′-azobis(2-amidino-
propane) dihydrochloride (AAPH, Sigma Aldrich, USA),
which by thermolysis at 40°C, generates peroxyl radicals
at a constant rate.
Thus, the antioxidants compete with the crocin for
ROO•; therefore, the inhibition of its oxidation depends
on the capacity of samples in capture the radical species
(Scheme 1).
To perform this test, the molar extinction coefficient
(ε) of crocin in DMSO was determined, as this solvent
was used to enhance its solubility and prepare the crocin
stock solution: ε = 13,726 M-1 cm-1, at 443 nm.
The crocin (25 μmol/L, Sigma Aldrich, USA) in so-
dium phosphate buffer 120 mmol/L, pH 7.0, was mixed
with various concentrations of uremic solutes. The reac-
tion was started by adding 12.5 mmol/L of AAPH and
performed at 40°C with constant stirring. The rate of
crocin bleaching (linear after about 1 minute of reaction)
was monitored at 443 nm for 10 minutes. To eliminate
possible interference from the sample, a reaction mix-
ture without crocin was prepared for each solute and
used as the reaction blank.
The rate of crocin bleaching by the generated peroxyl
radical (v0) decreases in the presence of an antioxidant,
as it competes with the crocin for the peroxyl radical,
and the new bleaching rate (v) is given by:
v ¼ v0  kc C½ kc C½  þ ka A½ 
where: v0 = k1 x [ROO
•] x [C]; kc = k1 x [ROO
•]; ka = k2 x
[ROO•]; [ROO•] = concentration of peroxyl radical; v0 = re-
action rate between crocin and ROO•; k1 = rate constant
Table 1 Uremic solute concentrations (mmol/L)
Uremic concentration (UC) Physiological concentration (PC)
1- L-arginine 0.230 0.140
2- Creatinine 0.880 0.120
3- p-cresol 0.280 0.021
4- Hippuric acid 1.700 0.028
5- Methylguanidine 0.091 0.006
6- Phenol 0.110 0.015
7- L-tyrosine 0.110 0.027
8- Urea 33.000 6.700
9- Uric acid 0.600 0.420
1 - UC [59], PC [60]; 2 - UC [61], PC [62]; 3 - UC [63], PC [64]; 4 - UC [61], PC [65]; 5 - UC [66], PC [66]; 6 - UC [67], PC [65]; 7- UC [68], PC [69]; 8 - UC [70], PC [62]; 9
- UC [61], PC [64].
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ROO•-antioxidant reaction; [C] = crocin concentration;
[A] = antioxidant (uremic solute) concentration.
The fall in crocin bleaching rate in the presence of an
antioxidant can be modeled as follows:
v0
v
¼ kc C½  þ ka A½ 





from the above equation,
The coefficient ka/kc, calculated as the slope of the re-
gression line for the v0/v versus [A]/[C] plot, indicates
the relative capacity of an antioxidant to interact with
the peroxyl radicals. By dividing this slope for a uremic
solute by the slope for a standard antioxidant such as
Trolox, the ratio of rate constants, and thus the relative
antioxidant capacity, of the analyzed compound can be
estimated, being expressed in Trolox equivalents.
Hydrogen peroxide scavenging assay
The H2O2 (Merck, German) oxidizes 2-nitro-5-thioben-
zoic acid (TNB, Sigma Aldrich, USA) to 5,5′-dithiobis-
2-nitrobenzoic acid (DTNB), with a decrease in absorb-
ance at 412 nm and increase at 325 nm [29].
The TNB solution was prepared by the method of
Ching et al. [30]; in 50 mmol/L potassium phosphate
buffer (pH 6.6) and its concentration was determined
from its molar extinction coefficient at 412 nm (13,600
M-1 cm-1; [31]); H2O2 concentration was determined as
described by Brestel [32], (ε = 80 M-1 cm-1, at 230 nm).
In 50 mmol/L potassium phosphate buffer pH 6.6,
various concentrations of uremic solutes were incubated
with H2O2 (0.3 mmol/L) for 30 minutes at 37°C. TNB (53
μmol/L) was added and incubated for 1 hour at 37°C. The
absorbance was read at 412 nm. Catalase (20 units/mL)
was used as a standard H2O2 scavenging agent.
The percent inhibition of TNB oxidation, i.e., percent
H2O2 capture, was calculated from the difference inabsorbance between reaction mixtures with and without
uremic solutes.Experiments with uremic solute mixtures
In view of the observed effectiveness of some of the
uremic solutes, viz. uric acid, p-cresol, phenol and L-
tyrosine, in assays with ABTS•+, HOCl/OCl− or ROO•,
further assays of their ability to scavenge these reactive
species were performed on mixtures of these four sol-
utes, in proportions based on their respective IC50.
These test mixtures were so designed that each of the
4 (or 2) solutes was present in the same proportion as
its IC50; thus, fractions or multiples of this volume
would correspond to the same fractions or multiples of
the IC50 of each of the uremic solutes. With this proced-
ure, if the scavenging effect of the solute mixture shows
independent activities of solutes, it would be additive
and exact, therefore the IC50 of the mixture would con-
tain ROS-scavenging activities of each component at
12.5% or 25% for 4 or 2 solutes, respectively, of its indi-
vidual IC50.Results
In vitro model systems were used to assay the antioxi-
dant activity against the reactive species: ABTS•+, O2
•-,
H2O2, HOCl/OCl
− and ROO• (crocin bleaching assay).
The assays were performed with uremic solutes at vari-
ous concentrations, chosen in relation to the upper limit
of the respective reference range for healthy people
(physiological concentration) and those found in the
serum of patients with CKD (mean uremic concentra-
tion), as listed in Table 1. The uremic solutes were
chosen according to the following criterion: i) classifica-
tion according to the size and binding properties [33]; ii)
highest uremic concentration/normal concentration ra-
tio [33]; iii) knowing antioxidant capacity of some
uremic solutes [14,34,35].







































































































Figure 1 Scavenging capacity of the uric acid and Trolox on the
ROS. (A) ABTS•+ scavenging capacity (IC50) of uric acid. The graph
inset shows the mean absorbance of ABTS•+, at 734 nm, for various
concentrations of uric acid. (B) HOCl/OCl− scavenging capacity (IC50)
of uric acid. The inset shows the mean absorbance of HOCl/OCl−, at
655 nm, for various concentrations of uric acid. (C) O2
•- scavenging
capacity (IC50) of Trolox. The inset shows the mean absorbance of
O2
•-, at 560 nm, for various concentrations of Trolox. The scavenging
capacities against oxidizing species were performed in triplicate
tests.
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In the ABTS•+ assay, the Trolox (standard) showed an
IC50 value of 16.45 ± 0.30 μmol/L. Uric acid, with anIC50 of 16.75 ± 0.14 μmol/L (Figure 1A) for ABTS
•+, was
as effective an antioxidant as Trolox.
The other solutes (Table 2) also show efficiency against
ABTS•+, with IC50 ranging from 4 μmol/L to 61 mmol/L
or higher: p-cresol < L-tyrosine < phenol < uric acid <
creatinine < L-arginine. Hippuric acid, methylguanidine
and urea did not have any effect on ABTS•+ at the tested
concentrations.
HOCl/OCl− scavenging by uremic solutes
In the HOCl/OCl− assay, most of the uremic solutes
proved to be effective in scavenging this ROS and, there-
fore, it was possible to measure their IC50 (Figure 1B).
However, methylguanidine, even at up to 10 times the
average uremic plasma level, had no effect on HOCl/
OCl−. Trolox was used as the standard, with an IC50 =
8.65 ± 0.39 μmol/L. Table 2 presents the values of IC50
for uremic solutes in this assay, from approximately 3
μmol/L up to 92 mmol/L or higher; the ascending order
of IC50 was: L-tyrosine < uric acid < phenol < p-cresol <
hippuric acid < urea < creatinine < L-arginine (descend-
ing order of effectiveness).
O2
•- scavenging by uremic solutes
The uremic solutes were tested at three concentrations:
physiological, uremic and 10 times the average uremic
level. None of the tested solutes were effective in scaven-
ging O2
•- at any tested concentration. Again, Trolox was
used as a standard, showing a relatively high value of
IC50 (≈2 mmol/L), but demonstrating that the test was
valid (Figure 1C).
H2O2 scavenging by uremic solutes
None of the uremic solutes at physiological, or up to 10
times uremic concentrations, or even Trolox (up to 6
mmol/L), captured H2O2 (data not shown), so we used
catalase to validate the test, because of its recognized ef-
ficiency and specificity in converting H2O2 to water and
oxygen [21]; for this enzyme, an IC50 of 0.55 units/mL
or 18.6 μg/mL (77.5 nmol/L, considering the molecular
weight, 240,000 Da [36]) was observed.
ROO• scavenging by uremic solutes
The ability of Trolox to inhibit crocin bleaching is
shown in Figure 2A. Comparing the values of the slope
(reaction rate) for the uremic solutes, the order of de-
creasing antioxidant capacity was: uric acid > p-cresol >
phenol > L-tyrosine (e.g. see Figure 2B, C, D, E). In the
presence of all the other solutes, the crocin bleaching
rate was unchanged, indicating a lack of interaction with
the peroxyl radical and, therefore, that these solutes did
not show antioxidant capacity against ROO•.
It is also possible to assess crocin bleaching in another
way, by determining the percent inhibition of crocin
Table 2 ROS scavenging activities of uremic solutes, expressed as concentration needed for 50% inhibition
(IC50 ± SEM*, μmol/L)
Solutes ABTS•+ O2
•- H2O2*** HOCl/OCl
− Crocin bleaching assay
L-arginine 61,350.00 ± 562.56 ** ** 92,100.00 ± 0.10 **
Creatinine 536.26 ± 3.32 ** ** 9,130.00 ± 0.10 **
p-cresol 3.99 ± 0.01 ** ** 15.75 ± 0.12 1,162.31
Hippuric acid ** ** ** 1,600.00 ± 0.01 **
Methylguanidine ** ** ** ** **
Phenol 12.98 ± 0.09 ** ** 8.95 ± 0.10 1,125.81
Trolox 16.45 ± 0.30 2,223.10 ± 0.17 ** 8.65 ± 0.27 10.09
L-tyrosine 5.23 ± 0.02 ** ** 2.83 ± 0.04 **
Urea ** ** ** 5,600.00 ± 0.20 **
Uric acid 16.75 ± 0.14 ** ** 5.75 ± 0.13 6.90
Values in μmol/L of IC50 of solutes; * SEM (standard error of the mean); ** No effect at the concentration used; *** Method was validated by reaction of H2O2
with catalase.
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that the IC50 values found for Trolox and uremic solutes
follow the same order of efficiency as the values of the
slopes in the competitive test (the lower the IC50 value,
the more efficient was the sample, and the greater the
slope of the reaction rate regression line, showing stron-
ger antioxidant activity) (Table 3).
It can be seen that uric acid, Trolox, phenol and p-cre-
sol exhibited significant antioxidant effects, while the
other solutes did not. It should be noted that only uric
acid produced an effect of the same order of magnitude
as Trolox, which shows its importance for the model
system of LPO, since its IC50 was lower than the physio-
logical concentration and its activity was approximately
twice that of Trolox (Table 3).Oxidant scavenging of uremic solute mixtures
Considering the four solutes: uric acid, p-cresol, phenol
and L-tyrosine that exhibited significant scavenging cap-
acity towards the three reactive species ABTS•+, HOCl/
OCl− and ROO•, we performed the assays with mixtures.
Therefore, the antioxidant behaviors of the mixtures of
these solutes were investigated, using the IC50 of each
solute against each ROS as a reference.
In the ABTS•+ or HOCl/OCl− scavenging assays for 4-
solutes mixtures, it was found practically the projected
volume of solute mixture needed for IC50 (39.85 μL and
41.70 μL, respectively) (Figure 3A and B). For both as-
says, the concentration of each solute is presented in
Table 4A and B, which represented about a quarter of its
individual IC50.
In the crocin bleaching assay, it was used to binary mix-
tures: uric acid + phenol; uric acid + p-cresol; phenol + p-
cresol, then it was found a high volume of solute mixture
needed for IC50 (150.3 μL, 126.5 μL, 152.5 μL, respect-
ively) (Figure 4A, B, C and Table 5).Discussion
In view of the quali-quantitatively wide variation of
uremic solutes found in biological fluids, and the ability
of some of these solutes to scavenge certain ROS, we
employed a broad set of measures of antioxidant cap-
acity, rather than a single measure, to obtain a highly
representative result. These analytical techniques were
chosen to reflect, as accurately as possible, the antioxi-
dant capacity of uremic solutes. Data from this study
showed that the uremic solutes p-cresol, phenol, L-
tyrosine and uric acid were effective antioxidants, mainly
through three model systems: ABTS•+, HOCl/OCl− and
crocin bleaching assay (Table 2). When mixtures of these
solutes where studied, it was found that, in 4-solutes
mixtures, each one of the solute captured 12.5% for the
IC50 in ABTS
•+ or HOCl/OCl− assays (Table 4A and B),
exhibiting a virtually exact additive effect; in 2-solutes
mixtures for ROO• capture, it was observed the need of
more mass of uremic solutes to reach an IC50 value of
mixtures, which was higher than the projected IC50 ob-
tained from the IC50 of single solutes (25% of each, in
the binary mixtures) (Table 5).
In the ABTS•+ assay, Trolox was used as “standard”
and showed an IC50 value similar that found with uric
acid (Figure 1A), as also noted by others [38,39]. In a
study of Gülçin [40], 79.90 μmol/L Trolox and 110.37
μmol/L L-tyrosine both proved to be effective, scaven-
ging 95% and 62% of ABTS•+, respectively. The presence
of hydroxyl groups and aromatic rings in the uremic sol-
utes appears to be correlated with their antioxidant ac-
tivity, since the most effective solutes were p-cresol, L-
tyrosine, phenol and uric acid (Table 2); this relationship
between structure and antioxidant capacity of com-
pounds has also been reported by others [40,41].
Mayer et al. [16] investigated the effect of HD on the
antioxidant capacity of serum patients using the ABTS•+
assay. The authors observed a decrease in serum total
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Figure 2 Reaction velocity ratios plotted against uremic solute (sample) concentrations in the crocin bleaching assay. (A) Trolox; (B) uric acid; (C)
p-cresol; (D) phenol; (E) L-tyrosine. [C], crocin concentration and [A], sample concentration. The inset shows the decrease in absorbance of crocin,
at 443 nm, over 10 min: (v0) velocity in the absence and (v) velocity in the presence of various concentrations of samples. The experimental
conditions are described in Methods. The ROO• scavenging assay was performed in duplicate testes.
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attributed to the dialytic removal of uric acid and ascorbic
acid. Similarly, Bianchi et al. [42] investigated the conse-
quences of an HD session on the systemic oxidative stressof CKD patients, assaying serum samples with the total re-
active antioxidant potential (TRAP) test; when pre- and
post-HD sera of CKD patients were compared, it was ob-
served a reduction in TRAP after one HD session.
Table 3 Comparison between competitive kinetic slopes
and IC50, for the crocin bleaching assay
Solutes Slope of regression line* IC50 (μmol/L)**







Hippuric acid 8.000x10−5 ***
Creatinine 6.776x10−5 ***
Urea 2.558x10−6 ***
*Regression line slopes in order of decreasing efficacy; **IC50 in order of
decreasing efficacy, from plot of equation: % In = (1- (Δv/Δvo)) × 100; ***IC50>
highest concentration tested.
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Figure 3 Capacity of the mixture of solutes uric acid, phenol, p-
cresol and L-tyrosine to scavenge (A) ABTS•+ and (B) HOCl/OCl−. The
inset of the figure (A) show the mean absorbance of ABTS•+, at 734
nm, for various volumes in the assay of the stock solute mixture
with: uric acid (33.5 μmol/L), phenol (25.96 μmol/L), p-cresol (7.98
μmol/L) and L-tyrosine (10.46 μmol/L); final volume reaction, 300 μL.
The inset of the figure (B) show the mean absorbance of HOCl/OCl−,
at 655 nm, for various volumes in the assay of the stock solute
mixture with: uric acid (57.5 μmol/L), phenol (89.5 μmol/L), p-cresol
(157.5 μmol/L) and L-tyrosine (28.3 μmol/L); final volume reaction,
1500 μL. The scavenging capacities against oxidizing species were
performed in triplicate tests.
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ture HOCl/OCl−, with exception of methylguanidine, which
showed no effect (Table 2). The relationship of uremic sol-
utes with HOCl/OCl− system seems to be relevant when
we consider the data about the increase in both the activity
and concentration of myeloperoxidase (MPO) in HD pa-
tients when compared with pre-HD and control subjects
[43,44]. Increased MPO activity in HD patients may be due
to the activation of neutrophils during the forced blood
passage through the dialysis circuits, which is related to the
precocity and prevalence of atherosclerotic disease in CKD
patients. In fact, increased levels of proteins modified by
HOCl generated by the MPO/H2O2/Cl
− system have been
found in serum of HD patients, such as oxidized albumin;
HOCl-modified albumin impairs the association of high-
density lipoprotein (HDL) with the scavenger receptor class
B type I, which have a protective role against atherosclerotic
cardiovascular disease [45]; also, it was found a direct rela-
tionship between plasma levels of oxidized low density lipo-
protein (ox-LDL) and MPO in CKD diabetic patients
during HD [46]. On the other hand, whereas most of the
uremic solutes scavenged ABTS•+ and HOCl/OCl− effect-
ively, the same did not happen with the other biological
ROS, O2
•- and H2O2 (Table 2).
O2
•- is an essential ROS, since it is a precursor for other
reactive species and it is constantly produced in the hu-
man body during physiological processes, such as the
mitochondrial electron transport chain and some signal-
ing events in the vascular system [21]. Its production is
also initiated in activated phagocytes into the oxidative
burst, leading to the synthesis of O2
•- and other ROS,
overcoming the local antioxidant capacity [21,47]. Thus,
increased O2
•- levels can, for example, contribute greatly
to the endothelial dysfunction and thus hinder the
process of vascular wall distention by scavenging NO to
generate peroxynitrite [7,21]. In this context, the mainmechanism by which L-arginine leads to beneficial ef-
fects on CKD has been attributed to an increase in the
NO production, since nitric oxide synthase (NOS) activ-
ity in kidney failure is determined by L-arginine concen-
tration [48]; so, L-arginine in CKD is important to
oppose endothelial dysfunction. In a review by Baylis
[49], it is pointed that the total NO production is de-
creased in CKD patients due to main possible causes: i)
the limitation of substrate (L-arginine) for NOS, and ii)
the increased levels of circulating endogenous inhibitors
of NOS, particularly asymmetric dimethylarginine.
According our data, none of the tested solutes were ef-
fective in scavenging O2
•- at any tested concentration
(Table 2). Our results corroborate those of Barreiros et al.
Table 4 Relations between the IC50 of the solutes uric acid, phenol, p-cresol and L-tyrosine for their scavenging of: (A)
ABTS•+, (B) HOCl/OCl− and the IC50 of mixed samples
Uremic solutes
in mixture
Volume (μL) of solute
mixture needed for IC50
Concentration (μmol/L)




Ratio of concentration of each
solute in the IC50 of the mixture
to its respective IC50, for ABTS
•+
A ABTS•+ ABTS•+ ABTS•+ ABTS•+




Phenol 3.45 12.98 0.26
Uric acid 4.45 16.75 0.26
B HOCl/OCl− HOCl/OCl− HOCl/OCl− HOCl/OCl−




Phenol 2.50 8.95 0.27
p-cresol 4.38 15.75 0.27
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•-
and H2O2, but showed strong reactivity with ROO
• and
NO2
• . In view of the high activity against ROO•, it has
been postulated that uric acid protects lipids and DNA
from the interaction with ROO•. While our findings of
O2
•- scavenging indicated that Trolox has a high IC50,
(Figure 1C), Ak and Gülçin [51] and Gülçin [40] re-
ported a greater efficiency of Trolox against O2
•-, when
they used a more sensitive chemiluminescent method,
with inhibition of 78.2% of O2
•- activity at 39.95 μmol/L,
indicating that these differences may be attributed to
methodological sensitivity.
Miyamoto et al. [35] showed that the uremic solutes
uric acid, p-cresol and indoxyl sulfate, under physio-
logical concentrations, they have potent antioxidant ac-
tivity, comparable to that of superoxide dismutase,
assessed by luminol chemiluminescence, which repre-
sents the ability to scavenge O2
•-. In this study, O2
•- was
generated from the xanthine/xanthine oxidase system,
and the authors found that, at least for indoxyl sulfate, it
did not inhibit the xanthine oxidase activity, confirming
that the antioxidant property of this solute is exclusively
due to its capacity to scavenge O2
•-.
H2O2 is produced in vivo continuously in virtually all
tissues. The mitochondria can contribute with the cellu-
lar generation of H2O2, by both monoamine oxidase ac-
tivity and dismutation of O2
•- generated in the electron
transport chain, although mitochondria can also con-
sume H2O2; thus, in in vivo systems, H2O2 is generated
by O2
•- dismutation, spontaneously or catalyzed by super-
oxide dismutase, as well as by β-oxidation of fatty acids
or directly by various oxidase enzymes [21]. None of the
uremic solutes or even Trolox at high levels captured
H2O2 (data not shown) (Table 2).
Lipid bilayer cell membranes are the main targets
of attack by free radicals, causing loss of membranestructure and functionality; therefore, LPO is a part of
the etiology of many diseases. Such serious conse-
quences of LPO have encouraged studies on the efficacy
and mechanisms of action of biological antioxidants, jus-
tifying the relevance in the understanding the activity of
uremic solutes against ROO•. In the crocin bleaching
assay, antioxidants compete with crocin for the ROO•
radical generated by AAPH thermolysis; therefore, the
inhibition of the oxidation of crocin depends on the cap-
acity of the samples to capture this radical species gener-
ated in situ. The solutes uric acid, p-cresol, phenol and
L-tyrosine, and Trolox, were effective in inhibiting the
crocin bleaching (Figure 2A, B and C; Tables 2 and 3); it
should be noted that only uric acid produced an effect
of the same order of magnitude as Trolox. It is interest-
ing to note that the increased circulating levels of uric
acid has been cited as a protective mechanism trying to
counteract LPO oxidation during atherosclerosis, al-
though this increase has been also associated with an el-
evated rate of disease and mortality [34].
The relationship between the antioxidant potential of
uremic solutes and the ability to prevent biological dam-
age was also assessed by Ujhelyi et al. [14]; the authors
showed that plasma ultrafiltrate from CKD patients ex-
hibited i) a pronounced antioxidant activity, assessed by
the ability to inhibit the heme-mediated LDL oxidation
(in vitro assay), and ii) protection against endothelial
cytotoxicity induced by LDL oxidation. This antioxidant
capacity of plasma ultrafiltrate from CKD patients was
lost after HD as a consequence of the dialytic removal of
some compounds, including the uremic solutes indoxyl
sulfate, p-cresol, phenol, and uric acid; in addition, it
was observed that the retention of other solutes, in-
cluding L-arginine, creatinine, guanidines, hippuric acid,
among others, was not sufficient to prevent the oxidative
modification of LDL. The presence or absence of















































































Figure 4 Effects of solute mixtures in the crocin bleaching
assay. (A) uric acid plus phenol; (B) uric acid plus p-cresol and (C)
phenol plus p-cresol. The insets show the mean rates of change of
absorbance, at 443 nm, in crocin bleaching plotted against amount
of solute mixture added: (A) stock solute mixture with: uric acid
(69.0 μmol/L) plus phenol (11,258.1 μmol/L), (B) stock solute mixture
with: uric acid (69.0 μmol/L) plus p-cresol (11,623.1 μmol/L) (C) stock
solute mixture with: phenol (11,258.1 μmol/L) plus p-cresol (11,623.1
μmol/L); final volume reaction, 2000 μL. The ROO• scavenging assay
was performed in duplicate testes.
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rated by our findings for the most of the uremic solutes.
At this time, it is appropriate to quote a sentence of
Ujhelyi et al. [52] in response to Meijers and colleagues,“p-cresol can be considered to be a Janus-faced com-
pound with several toxic and some beneficial properties,
and it might be a marker of pathologic metabolic pro-
cesses that lead to the observed enhanced risk of mortal-
ity in hemodialysis patients”. This Janus-faced feature
has been also attributed to other solutes, such as uric
acid [53] and indoxyl sulfate [35,54].
Bianchi et al. [42] assessed the oxidative damage of
lipids in erythrocytes of CKD patients by chemilumines-
cence assays for LPO initiated by tert-butyl hydroperox-
ide (t-BOOH), which are sensitive and have been used to
observe indirectly the previous oxidative stress and
diminished endogenous antioxidants [55,56]. When
chemiluminescence data from pre- and post-HD patients
were compared, no differences were observed, but an in-
creased chemiluminescence was observed when pre-HD
patients were compared with healthy subjects, showing a
state of oxidative stress in these patients. It is important
to note that the crocin bleaching test allows the analysis
of the antioxidant effect of uremic solutes, i.e., how
much they prevent the LPO process.
Recently, an interesting approach to evaluate the rela-
tionship between uremic solutes and oxidative stress was
proposed by Oowada et al. [19]: the authors used a com-
mon experimental procedure to produce ROS (UV/vis-
ible-light photolysis of free radical precursors/
sensitizers), and they made a radar chart based on the
recording of the electron spin resonance spectrum using
spin traps; this approach was used to assess the scaven-
ging capacity of serum samples. The authors observed
that serum samples of CKD patients showed decreased
scavenging capacity against •OH and methyl (•CH3) radi-
cals and singlet oxygen (1O2), increases for O2
•- and RO•
radicals, and no changes for ROO• radical in comparison
to healthy individuals. It is interesting to note that the
authors did not explain these changes in the scavenging
capacity, but they highlight for the future application of
this approach as a tool for clinical uses.
Given that in the body and especially under uremic
conditions, there is always a complex mixture of uremic
solutes, it would clearly be of interest to analyze the ef-
fects of a mixture of the four solutes, uric acid, p-cresol,
phenol and L-tyrosine, that exhibited significant scaven-
ging capacity towards the three reactive species ABTS•+,
HOCl/OCl− and ROO•. In the ABTS•+ and HOCl/OCl−
scavenging assays carried out with the 4-solutes mixture,
it was found that at the IC50, the concentration of each
solute was about a quarter of its individual IC50
(Table 4A and B).
In view of the complexity of the crocin bleaching
assay, in which antioxidants compete dynamically with
the crocin to react with the radical species generated in
situ, the mixed-solute in this assay was restricted to bin-
ary mixtures. To scavenge ROO•, it was need more mass
Table 5 Relations between the IC50 of the solutes uric acid, phenol and p-cresol determined in the crocin bleaching

















(μmol/L) of the binary
mixtures of uremic solutes







Uric acid + Phenol 150.3 5.18 846.04 --- 851.22 6.90 1125.81 --- 566.35
Uric acid +
p-cresol
126.5 4.36 --- 735.16 739.52 6.90 --- 1162.31 584.60
Phenol +
p-cresol
152.5 --- 858.43 886.26 1744.69 --- 1125.81 1162.31 1144.06
*The projected total concentration at the IC50 of the binary mixtures, for example, uric acid + phenol is (6.90 + 1125.81)/2 = 566.35.
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tures, which was therefore higher than the projected
IC50, obtained from the of the IC50 of single solutes
(25% of each, in the binary mixtures) for the same assay
(Table 5). Similarly, using the ORAC (oxygen radical ab-
sorbance capacity) method, Noguer et al. [57] observed
that binary mixtures of uric acid or ascorbic acid with
the phenolic compound 3-hydroxyphenylacetic acid
showed a diminished antioxidant activity in comparison
with the theoretical values obtained from the sum of the
activity of each compound individually. Taken together,
it can be suggested the existence of an interaction be-
tween phenol and/or phenolic derivatives with uric acid
or even with other antioxidant compounds. In front of
these findings, it seems extremely useful the monitoring
the effectiveness of the antioxidant status of biological
samples (mixtures), mainly under conditions of altered
levels of the endogenous antioxidant network and/or
after the employment of exogenous antioxidant therapy.
Considering our findings, the IC50 showed to be a
valuable analytical tool, as knowing the values of IC50
for each solute, it was possible to weigh their ROS-
scavenging capacities in mixtures of solutes. This ana-
lysis was accurate and exact for the assays in which the
ROS were present in the initial mixture (ABTS•+, HOCl/
OCl−), but was not exact for those in which they were
generated in situ (crocin bleaching assay, ROO•). Thus,
the application of the IC50 as an analytical tool to mix-
tures of solutes enables their individual antioxidant ac-
tivities to be investigated in biological fluids containing
such mixtures, over a range of concentrations and in
varied pathophysiological states with or without antioxi-
dant therapy, such as those provoked by kidney disease.
Conclusions
From the results of this study, we can conclude that the
same set of uremic solutes, uric acid, p-cresol, phenol and
L-tyrosine, showed significant antioxidant activity in the
ABTS•+, HOCl/OCl− and crocin bleaching (ROO• capture)assays, albeit with differing efficiencies. The values of IC50
found, in the three assays where the set of four uremic sol-
utes were effective, they were below physiological concen-
trations, as demonstrated by their behavior both separately
or combined. It must be emphasized, however, that for O2
•-
and H2O2, which are extremely important endogenous
ROS produced during oxidative stress, no uremic solute
showed scavenging capacity.
Thus, it could be interesting to knowledge the behav-
ior (IC50) of theoretical mixtures and compare them
with real biological samples using, for example, an ana-
lytical approach to generate ROS and to monitor their
specific scavenging capacities, as the model proposed by
Oowada and collaborators [19]. Finally, the combined
use of these analytical tools may be useful for the assess-
ment of the oxidative status of CKD and HD patients, as
well as to project and to monitor the effectiveness of
antioxidant interventions.
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